deniskatz

  Executive Summary For decades, neurology has operated within a syndromic framework grouping patients by observable symptoms rather than underlying biology. That model is reaching its limits. CNS disorders are now being redefined through molecular signatures, circuit-level dysfunction, and digital phenotypes . This is not a technological evolution it is a structural reset of how drugs are developed, evaluated, and approved. Sponsors who continue to build programs around broad diagnostic categories and legacy endpoints will increasingly fail not because their science lacks merit, but because their development strategy is misaligned with biological reality. Salience Clinical operates at the intersection of neuroscience, regulatory strategy, and precision development helping sponsors translate biological complexity into approvable labels, differentiated value , and durable market position . Target Audience: Chief Medical Officers, Heads of R&D, and Clinical Development Leaders a...